StockNow
Log in
U.S. Markets

Eli Lilly (LLY) says at week 52, Taltz and Zepbound further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed in the TOGETHER-PsO and TOGETHER-PsA trials

StockNow breaking-news AI analysis

Eli Lilly reported 52-week clinical data demonstrating that Taltz combined with Zepbound further improved psoriasis and psoriatic arthritis disease activity over Taltz alone in TOGETHER trials.

1 stocks
LLYEli Lilly & Co.$1,172.00Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

[MARKET UPDATE] Modest downside in Energy benchmarks as newswires re-run comments from Iranian President Pezeshkian, supporting equities and weighing on the USD

Geopolitics

US President Trump posts that Iran is a “failed nation,” claiming its military, economy and leadership are in disarray while accusing the government of killing protesters and spreading misinformation

Geopolitics

US President Trump says US will respond to Iranian attacks, reports Fox

FOXFOXA